Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8413192 | 1.00 | GABRR1 (0.39) | GABRR1ALDH1A1LMNAPOLBGRM4 | |
| SCHEMBL1030281 | 1.00 | GABRR1 (0.39) | GABRR1ALDH1A1LMNAPOLBGRM4 | |
| SCHEMBL1030622 | 1.00 | GABRR1 (0.39) | GABRR1ALDH1A1LMNAPOLBGRM4 | |
| SCHEMBL8261790 | 0.88 | GABRR1 (0.37) | GABRR1ALDH1A1LMNAPOLBGRM4 | |
| SCHEMBL1225729 | 0.86 | GABRR1 (0.31) | GABRR1 | |
| SCHEMBL12956004 | 0.84 | HDAC4 (0.39) | ALDH1A1LMNAPOLBKMT2ATDP1 | |
| SCHEMBL13678759 | 0.83 | ALDH1A1 (0.38) | GABRR1ALDH1A1LMNAPOLB | |
| Icofungipen SCHEMBL6268842 | 0.83 | GABRR1 (0.48) | GABRR1ALDH1A1GRM4CYP2C19MEN1 | |
| Icofungipen SCHEMBL6268839 | 0.83 | GABRR1 (0.48) | GABRR1ALDH1A1GRM4CYP2C19MEN1 | |
| Icofungipen SCHEMBL3950387 | 0.83 | GABRR1 (0.48) | GABRR1ALDH1A1GRM4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814855-B1 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20060106016-A1 | Dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-05-18 | — | — | US | claimed |
| EP-1256568-A1 | Intermediates for the preparation of enantiomerically pure cyclopentane and cyclopentene beta amino acids | BAYER AG (DE) | 2002-11-13 | — | — | EP | disclosed |
| EP-0788473-B1 | NOVEL HIGH ENANTIO-SELECTIVE PROCESS FOR PRODUCING PURE ENANTIOMERIC CYCLOPENTANE AND CYCLOPENTENE-BETA-AMINO ACIDS | BAYER AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-5962724-A | FROM THE CORRESPONDING MESODICARBOXYLIC ACID ANHYDRIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-05 | — | — | US | disclosed |
| EP-0788473-A1 | NOVEL HIGH ENANTIO-SELECTIVE PROCESS FOR PRODUCING PURE ENANTIOMERIC CYCLOPENTANE AND CYCLOPENTENE-BETA-AMINO ACIDS | BAYER AG (DE) | 1997-08-13 | — | — | EP | disclosed |
| EP-0454121-B1 | Azatetracyclic compounds | SEARLE & CO (US) | 1996-11-13 | — | — | EP | disclosed |
| US-RE35218-E | FOR GASTROINTESTINAL DISORDERS | G. D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| WO-1995019337-A1 | NOVEL HIGH ENANTIO-SELECTIVE PROCESS FOR PRODUCING PURE ENANTIOMERIC CYCLOPENTANE AND CYCLOPENTENE-β-AMINO ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-20 | — | — | WO | disclosed |
| US-5223613-A | Prepared from cyclopenta(c)pyrrole derivatives; drug intermediates; antiemetics, anixiolytics | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5140023-A | Serontonin antagonist; gastrointestinal and psychological disorders; analgesics; antidepressants | G. D. SEARLE & CO. (US) | 1992-08-18 | — | — | US | disclosed |
| EP-0454121-A2 | Azatetracyclic compounds | G.D. Searle & Co. (US) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106016-A1 | Dicarboxamide derivatives | F2, F12, TFPI | GABRR1 2173/4885ALDH1A1 1180/4885LMNA 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.